HALO - Halozyme Quarterly EPS earnings growth

Halozyme Corp (HALO) - corporate logo

The ENHANZE technology solves the complexity of converting intravenous agents into subcutaneous forms, which confirms the quarterly EPS growth trend on the GURU.Markets chart, where the value of 40.30 reflects this status. The success of Halozyme Therapeutics (HALO) is based on the trust that pharma behemoths place in their scientific authority. Process efficiency is enhanced through the implementation of robotic stations that automate drug screening and reduce costs.

halozyme.com (HALO) - Year-over-year earnings per one share growth for the last 12 months from 07/04/2022 to 11/18/2026

Financial and market metric breakdowns for halozyme.com (HALO)

- market value and analyst target forecast:
Comprehensive company analysis:Halozyme, HALO
Manufactured product of Halozyme Therapeutics

Quarterly earnings per share growth measures the rate of change in net yield, serving as a fundamental quality filter for assets within the alpha model. By analyzing this quarterly EPS chart, an investor sees a daily approximation of data that eliminates information gaps between reports. A declining curve warns of an impending price drawdown. For Halozyme Therapeutics (HALO), this trend reflects the efficiency of the ENHANZE technology licensing. Steady growth in this metric confirms the inflow of royalties from biopharmaceutical partners.

Competing companies

ONC: Quarterly EPS earnings growth|RevMed - Year-over-year earnings per one share growth for the last 12 months|AAPG (Ascentage Pharma Group International) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months CG Oncology, Inc. CGON|Year-over-year net earnings per share growth for the last 12 months URGN (urogen.com)|Year-over-year earnings per share growth for the last twelve months BCAX (Bicara Therapeutics)|Quarterly EPS earnings growth PSNL (personalis.com)|Year-over-year earnings per one share growth for the last 12 months ERAS|DCTH - Year-over-year earnings per share growth for the last twelve months|Y-mAbs Therapeutics (YMAB) - Year-over-year net earnings per share growth for the last 12 months|AURA: Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months CADL|Year-over-year earnings per share growth for the last twelve months Accuray Inc.|SELLAS Life Sciences Group (SLS) - Year-over-year net earnings per share change for the last twelve months|Year-over-year net earnings per share growth for the last 12 months ACTU (Actuate Therapeutics, Inc)|Year-over-year net earnings per share change for the last twelve months Citius Oncology|TuHURA Biosciences, Inc. - Year-over-year net earnings per share growth for the last 12 months|Quarterly EPS earnings growth Protara TARA|fatetherapeutics.com - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Aadi Bioscience|TCRX: Quarterly EPS earnings growth|CSBR - Year-over-year net earnings per share change for the last twelve months|XBIT (XBiotech) - Quarterly EPS earnings growth|CVM: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth OSTX|RADX (Radiopharm Theranostics Limited) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth ARTV (Artiva Biotherapeutics, Inc.)|Year-over-year earnings per one share growth for the last 12 months ANL|VERU: Year-over-year net earnings per share growth for the last 12 months|TPST - Quarterly EPS earnings growth|XLO (xiliotx.com) - Year-over-year net earnings per share growth for the last 12 months|Renovaro Biosciences - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months MURA|Year-over-year earnings per share growth for the last twelve months KAPA|Year-over-year net earnings per share growth for the last 12 months OKUR (OnKure Therapeutics Inc)|Quarterly EPS earnings growth CytoMed (GDTC)|Year-over-year earnings per share growth for the last twelve months curis.com CRIS|APLM (Apollomics, Inc.) - Year-over-year net earnings per share trend for the last twelve months|Tharimmune Corporation - Quarterly EPS earnings growth|ADVB (advanbiomed.com) - Year-over-year earnings per share growth for the last 12 months|Genprex, Inc (GNPX) - Year-over-year earnings per share growth for the last twelve months|CLDI: Year-over-year earnings per share growth rate for the last twelve months|SBFM (Sunshine Biopharma, Inc.) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months XBIO (Xenetic Biosciences)|Quarterly EPS earnings growth SLRX|Purple Biotech - Year-over-year earnings per share growth for the last 12 months|American Oncology Network - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months BGNE|CKPT - Year-over-year earnings per share growth for the last twelve months|Elevation Oncology (ELEV) - Year-over-year net earnings per share growth for the last 12 months|ICAD: Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Ikena Oncology Inc.|NTBL (Notable Labs Ltd) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Viracta Therapeutics (VIRX)|Year-over-year earnings per share growth for the last twelve months MorphoSys Corporation (MOR)|NAYA (NAYA Biosciences) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth AAPGV (Ascentage)